Some recent M&A deals FYI. Lots of activity in the cancer space. Apologies for editing. HC not that user friendly
COMPANY ACQUIRED DATE OF DEAL TOTAL CONSIDERATION PRICE PER SHARE PREMIUM
Johnson & Ambrx Biopharma 1/8/24 $2,000M $28.00 105%
Johnson
Merck & Co. Harpoon Therapeutics c1/8/24 $680M $23.00 118%
AstraZeneca Gracell 12/26/23 $1,000M $2.00 62%
Bristol Myers RayzeBio 12/26/23 $4,100M $62.50 104%
Squibb
Bristol Myers Karuna Therapeutics 12/22/23 $14,000M $330.00 53%
Squibb
AbbVie Cerevel Therapeutics 12/6/23 $8,700M $45.00 22%
AbbVie ImmunoGen 11/30/23 $10,100M $31.26 95%
Eli Lilly Point Biopharma 10/3/23 $1,400M $12.50 87%
Ann: Notification regarding unquoted securities - NEU, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.23 |
Change
0.380(2.96%) |
Mkt cap ! $1.626B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.34 | $12.92 | $3.683M | 281.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 359 | $13.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.23 | 158 | 3 |
View Market Depth
| Last trade - 11.40am 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |